Search Results
Apr 20, 2026, 08:06 ET NCCN Announces Annual Awards to Honor Leaders Who Help Expand the Reach for Essential Cancer Care Resources
on multidisciplinary care, with the patient front and center.Dr. Riely serves as Chair of the NCCN Guidelines Panel for Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas. He is known for his depth of knowledge, ability to conceptualize complex information for the NCCN
More news about: National Comprehensive Cancer Network
Apr 20, 2026, 08:00 ET Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
target overexpressed in a broad range of solid tumors (i.e., head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer, among others), with limited expression in normal tissues.ADCE-T02 is currently being evaluated as a monotherapy
More news about: Adcendo
Apr 20, 2026, 08:00 ET Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
target overexpressed in a broad range of solid tumors (i.e., head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer, among others), with limited expression in normal tissues.ADCE-T02 is currently being evaluated as a monotherapy
More news about: Adcendo
Apr 20, 2026, 08:00 ET Deck Bio Presents Preclinical Data on DBXO-1, a Multi-pMHC Targeted T Cell Engager, at AACR 2026
initial clinical development is expected to focus on biomarker-selected patient populations across major solid tumor indications, including non-small cell lung and gastroesophageal cancers, representing an estimated addressable patient population of approximately 120,000 biomarker-positive patients in the first-line
More news about: Deck Bio, Inc.
Apr 20, 2026, 07:00 ET Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
improve outcomes for a broad spectrum of lung cancer patients."The featured Genprex-supported abstracts and posters presented at AACR 2026:Title: "TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer (NSCLC)"Session Category:
More news about: Genprex, Inc.
Apr 20, 2026, 06:45 ET U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV.Pneumonitis/Interstitial Lung Disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD occurred in patients treated with PADCEV.When PADCEV was given in combination
More news about: Astellas Pharma Inc.
Apr 20, 2026, 06:00 ET Top 5 Gundry MD Total Restore Reviews: Will It Improve Your Gut Health?
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Today, he is the founder and medical director of The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he has spent the past 25 years helping people restore
More news about: Gundry MD
Apr 20, 2026, 02:30 ET New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore
patients with extensive-stage small cell lung cancer (ES-SCLC) [1],[2]SCLC is an aggressive form of lung cancer, accounting for 10-15% of all lung cancer diagnoses [3]-[6]Lung cancer is the leading cause of cancer
More news about: Specialised Therapeutics
Apr 20, 2026, 02:05 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
Apr 19, 2026, 20:48 ET 【直擊AACR 2026】亞盛醫藥公布四項臨床前進展，展現多重聯合治療潛力
V600E突變的黑色素瘤和CRC中的進一步臨床開發潛力。（摘要編號：4500）Embryonic ectoderm development (EED) inhibitor APG-5918 synergizes with topoisomerase I inhibitors in preclinical small-cell lung cancer (SCLC) models through epigenetic priming of chemosensitivity胚胎外胚層發育蛋白 EED 抑制劑 APG-5918 通過表觀遺傳調控增強化療敏感性，在小細胞肺癌（SCLC）臨床前模型中與拓撲異構酶
More news about: 亞盛醫藥
Apr 19, 2026, 20:15 ET CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
CS5007 exhibits potent, nanomolar-level, antigen-dependent cell-killing activity across a broad spectrum of tumor cell lines, including non-small cell lung cancer (NSCLC), squamous cell carcinoma (SCC), colorectal cancer (CRC), squamous cell carcinoma (SCCHN), pancreatic cancer (PANC), and breast cancer
More news about: CStone Pharmaceuticals
Apr 19, 2026, 18:00 ET Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
present in ~70% of tumors. HWK‑007 is being evaluated in an ongoing Phase 1 clinical trial in patients with non-squamous, EGFR wild-type non-small cell lung cancer; platinum-resistant ovarian cancer; and endometrial cancer (NCT07444814). Key preclinical findings include:High‑affinity
More news about: Whitehawk Therapeutics, Inc.
Apr 18, 2026, 19:44 ET BREAKTHROUGH PRIZE ANNOUNCES 2026 LAUREATES
Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, and Howard Hughes Medical InstituteSwee Lay Thein, National Heart, Lung and Blood Institute, National Institutes of HealthFor elucidating the mechanism driving the switch from fetal to adult hemoglobin and validating
More news about: Breakthrough Prize
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
documents subsequently submitted to the Hong Kong Stock Exchange.For more information, please contact:Investor Contacts: Donald LungE-mail: [email protected] BD Contacts:Ariel
More news about: Antengene Corporation Limited
Apr 17, 2026, 18:01 ET ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
worldwide, with early-life infection linked to potential longer-term effects including recurrent wheeze or asthma, repeat hospital admissions and impaired lung health.In England, a national maternal RSV vaccination programme was introduced on 1 September 2024, offering the Bivalent Prefusion F vaccine
More news about: ESCMID Global
Apr 17, 2026, 18:01 ET ESCMID Global: Maternal RSV vaccination cuts infant hospitalisation risk by over 80%, major UKHSA study finds
worldwide, with early-life infection linked to potential longer-term effects including recurrent wheeze or asthma, repeat hospital admissions and impaired lung health.In England, a national maternal RSV vaccination programme was introduced on 1 September 2024, offering the Bivalent Prefusion F vaccine
More news about: ESCMID Global
Apr 17, 2026, 17:30 ET Brayton Purcell LLP Announces Expanded California Effort Supporting Cal/OSHA Petition to Prohibit High-Silica Artificial Stone; Highlights Capital & Main Investigation on Federal Liability Shield
petition to Cal/OSHA requesting a prohibition on artificial stone slabs containing more than 1% crystalline silica, citing the rapid rise of severe lung disease in countertop fabrication workers and the limitations of existing controls in preventing disease.Brayton Purcell LLP has supported the
More news about: Brayton Purcell LLP
Apr 17, 2026, 16:01 ET New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
across all lines of therapy.Based on results for tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) enrolled in the global registrational ARROS-1 Phase 1/2 clinical trial, the U.S. Food and Drug Administration (FDA) has accepted for
More news about: Nuvalent, Inc.
Apr 17, 2026, 15:00 ET Meiji Holdings Co., Ltd. Highlights that Yogurt Containing Bacteria Metabolite Shows a Tendency Toward Higher Response When Added to Immune Checkpoint Inhibitor Therapy in People Living with Non-small Cell Lung Cancer
NSCLC is the most common type of lung cancer, making up about 80% to 85% of all lung cancer cases. ICIs, including anti–PD–1 antibodies, are widely used as therapeutic agents for many types of cancer including lung cancer. While these treatments can produce significant benefits
More news about: Meiji Holdings Co Ltd
Apr 17, 2026, 15:00 ET Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting
of chromosomal instability. The molecule showed potent in vitro activity in high-grade serous ovarian cancer (HGSOC), squamous non-small cell lung cancer (sqNSCLC), and triple-negative breast cancer (TNBC) cell lines, leading to cell cycle arrest and apoptosis. ATX-295 showed robust and durable
More news about: Accent Therapeutics
Apr 17, 2026, 15:00 ET Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
conducted with Agilent Technologies and Ajou University Medical Center, researchers used Lunit SCOPE IO and uIHC to analyze over 25,000 non-small cell lung cancer (NSCLC) samples. The results showed that tumors with high c-MET expression exhibited a significant reduction in immune cell density within 30
More news about: Lunit
Apr 17, 2026, 14:26 ET "It Makes Me Feel Like I'm Growing Younger and Stronger" - Gundry MD Phyto Collagen Complex Receives Rave Reviews Highlighting Benefits of Full-Body Collagen Support
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Today, he is the founder and medical director of The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he has spent the past 25 years helping people restore
More news about: Gundry MD
Apr 17, 2026, 08:00 ET Ultima Genomics releases groundbreaking TRACERx MRD data showing ppmSeq performance and unveils clinical progress of whole genome sequencing at inaugural global MRD Symposium at AACR 2026
funded by Cancer Research UK to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients.Led by Professor Charles Swanton (UCL / Cancer Research UK / The Francis Crick Institute), an early validation pilot of ppmSeq
More news about: Ultima Genomics
Apr 17, 2026, 06:00 ET Harbinger Health Presents Multiple Studies at AACR Reinforcing Platform Foundation for RESOLVE™, a New Category for Cancer Detection
methylation predicts lung tumor size and metastatic potential in a single assayDate/Time: Monday, April 20, 2026, at 2:00pm PTKey Takeaways:Using cfDNA methylation data from the CORE‑HH clinical study, Harbinger developed models that infer lung cancer progression,
More news about: Harbinger Health
Apr 16, 2026, 11:03 ET /C O R R E C T I O N -- Boehringer Ingelheim/
(ERBB2)-mutant non-small cell lung cancer (NSCLC)Lung cancer claims more lives than any other cancer type3 and the incidence is set to increase to over 3 million cases worldwide by 2040.4 NSCLC is the most common type of lung cancer.3 The condition is
More news about: Boehringer Ingelheim